Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.32 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.32 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.32 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL345654 | 0.84 | GABRA5 (0.38) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL1222696 | 0.81 | SLC6A2 (0.36) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| Hydrochloric Acid SCHEMBL25406552 | 0.80 | SLC6A2 (0.35) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL27166484 | 0.75 | ITGB3 (0.41) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL17200854 | 0.74 | SSTR4 (0.35) | — | |
| SCHEMBL854782 | 0.73 | ALDH1A1 (0.31) | — | |
| SCHEMBL18497604 | 0.73 | SLC6A1 (0.32) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL222367 | 0.72 | SLC6A1 (0.49) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL222368 | 0.72 | SLC6A1 (0.49) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL3613801 | 0.72 | SLC6A1 (0.49) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INTS9, CDK8, SCN8A | SLC6A1 791/4885GABRA5 258/4885GABRB2 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.